Influence of APOE ε4 on performance of CSF biomarkers in differentiating clinical Alzheimer's disease

被引:0
|
作者
Wang, Yan [1 ,2 ]
Li, Fangyu [1 ,2 ]
Qin, Qi [1 ,2 ]
Li, Tingting [1 ,2 ]
Wang, Qi [1 ,2 ]
Li, Yan [1 ,2 ]
Li, Ying [1 ,2 ]
Jia, Jianping [1 ,2 ,3 ,4 ,5 ]
机构
[1] Capital Med Univ, Xuanwu Hosp, Innovat Ctr Neurol Disorders, Natl Clin Res Ctr Geriatr Dis, Beijing, Peoples R China
[2] Capital Med Univ, Xuanwu Hosp, Natl Clin Res Ctr Geriatr Dis, Dept Neurol, Beijing, Peoples R China
[3] Capital Med Univ, Clin Ctr Neurodegenerat Dis & Memory Impairment, Beijing, Peoples R China
[4] Capital Med Univ, Beijing Inst Brain Disorders, Ctr Alzheimers Dis, Collaborat Innovat Ctr Brain Disorders, Beijing, Peoples R China
[5] Minist Educ, Key Lab Neurodegenerat Dis, Beijing, Peoples R China
来源
JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE | 2025年 / 12卷 / 04期
基金
中国国家自然科学基金; 美国国家卫生研究院;
关键词
Alzheimer's disease; Apolipoprotein E; Mild cognitive impairment; Biomarker; Cognitive decline; CEREBROSPINAL-FLUID; TAU; METAANALYSIS; LOCI; BETA;
D O I
10.1016/j.tjpad.2025.100065
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: Apolipoprotein E epsilon 4 (APOE epsilon 4) bring the higher risk of Alzheimer' Disease (AD). It is essential to evaluate whether the diagnostic performances and critical values of cerebrospinal fluid (CSF) biomarkers are influenced by APOE epsilon 4, which has guiding significance for the clinical practical application. Methods: The differences in CSF biomarkers and their performances between APOE epsilon 4 carriers and non-carriers in distinguishing AD, mild cognitive impairment (MCI) and preclinical AD from normal controls (NCs) were analyzed. The receiver operating characteristic (ROC) curves were generated to compare the area under the curve (AUC) between APOE epsilon 4 carriers and non-carriers, as well as the critical values corresponding Youden Index. Results: In a cross sectional convenience sample of 1610 participants, lower A beta 42 and A beta 42/A beta 40 and higher p-Tau 181/A beta 42 in CSF were observed among APOE epsilon 4 carriers than non-carriers in NC, MCI, and AD groups (P< 0.05). The performance of CSF p-tau/A beta 42 in distinguishing MCI from NC among APOE epsilon 4 carriers was superior to non-carriers [AUC: 0.714 (95%CI: 0.673- 0.752) vs 0.600 (95%CI: 0.564- 0.634), P< 0.001], although it was similar in distinguishing AD from NC between APOE epsilon 4 carriers and non-carriers [AUC: 0.874 (95%CI: 0.835-0.906) vs 0.876 (95%CI: 0.843- 0.904)]. In the longitudinal cohort of 254 participants, the association of CSF A beta 42, A beta 42/A beta 40 and p-Tau181/A beta 42 with cognitive decline were stronger in APOE epsilon 4 carriers compared to non-carriers (P< 0.05). Meanwhile, the critical values were different depending on APOE genotype. Discussion: The CSF level of p-Tau181/A beta 42 was significantly different between APOE epsilon 4 carriers and non-carriers at different stages of AD. The results indicate that the performances of CSF biomarkers are influenced by APOE epsilon 4, which should be considered in the practical application.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Longitudinal Changes of CSF Biomarkers in Alzheimer's Disease
    Seppala, Toni T.
    Koivisto, Anne M.
    Hartikainen, Paivi
    Helisalmi, Seppo
    Soininen, Hilkka
    Herukka, Sanna-Kaisa
    JOURNAL OF ALZHEIMERS DISEASE, 2011, 25 (04) : 583 - 594
  • [2] Influence of APOE Genotype on Alzheimer's Disease CSF Biomarkers in a Spanish Population
    Monge-Argiles, J. A.
    Gasparini-Berenguer, R.
    Gutierrez-Agullo, M.
    Munoz-Ruiz, C.
    Sanchez-Paya, J.
    Leiva-Santana, C.
    BIOMED RESEARCH INTERNATIONAL, 2016, 2016
  • [3] Clinical indications for analysis of Alzheimer's disease CSF biomarkers
    Engelborghs, S.
    REVUE NEUROLOGIQUE, 2013, 169 (10) : 709 - 714
  • [4] Use of CSF biomarkers in the diagnosis of Alzheimer's disease in clinical practice
    Koric, L.
    Felician, O.
    Ceccaldi, M.
    REVUE NEUROLOGIQUE, 2011, 167 (6-7) : 474 - 484
  • [5] Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting
    Dumurgier, Julien
    Vercruysse, Olivier
    Paquet, Claire
    Bombois, Stephanie
    Chaulet, Chloe
    Laplanche, Jean-Louis
    Peoc'h, Katell
    Schraen, Susanna
    Pasquier, Florence
    Touchon, Jacques
    Hugon, Jacques
    Lehmann, Sylvain
    Gabelle, Audrey
    ALZHEIMERS & DEMENTIA, 2013, 9 (04) : 406 - 413
  • [6] Alzheimer's disease CSF biomarkers: clinical indications and rational use
    Niemantsverdriet, Ellis
    Valckx, Sara
    Bjerke, Maria
    Engelborghs, Sebastiaan
    ACTA NEUROLOGICA BELGICA, 2017, 117 (03) : 591 - 602
  • [7] The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease
    Glodzik-Sobanska, Lidia
    Pirraglia, Elizabeth
    Brys, Miroslaw
    de Santi, Susan
    Mosconi, Lisa
    Rich, Kenneth E.
    Switalski, Remigiusz
    Saint Louis, Leslie
    Sadowski, Martin J.
    Martiniuk, Frank
    Mehta, Pankaj
    Pratico, Domenico
    Zinkowski, Raymond P.
    Blennow, Kaj
    de Leon, Mony J.
    NEUROBIOLOGY OF AGING, 2009, 30 (05) : 672 - 681
  • [8] CSF Biomarkers in Alzheimer's Disease and Controls: Associations with APOE Genotype are Modified by Age
    Kester, Maartje I.
    Blankenstein, Marinus A.
    Bouwman, Femke H.
    van Elk, Evert J.
    Scheltens, Philip
    van der Flier, Wiesje M.
    JOURNAL OF ALZHEIMERS DISEASE, 2009, 16 (03) : 601 - 607
  • [9] APOE ε4 Allele Is Associated with Elevated Levels of CSF VILIP-1 in Preclinical Alzheimer's Disease
    Wang, Lijun
    Zhang, Miao
    Wang, Qian
    Jiang, Xianguo
    Li, Kunyi
    Liu, Jun
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2020, 16 : 923 - 931
  • [10] Alzheimer’s disease CSF biomarkers: clinical indications and rational use
    Ellis Niemantsverdriet
    Sara Valckx
    Maria Bjerke
    Sebastiaan Engelborghs
    Acta Neurologica Belgica, 2017, 117 : 591 - 602